Application of liposomal technologies for delivery of platinum analogs in oncology.
Application of liposomal technologies for delivery of platinum analogs in oncology.
复制标题
DOI：
10.2147/ijn.s38354
复制
发表时间：
2013
影响因子：
8
通讯作者：
Lin W
中科院分区：
文献类型：
--
作者：
Liu D;He C;Wang AZ;Lin W
铂类化疗，例如顺铂、奥沙利铂和卡铂，是最广泛使用的癌症治疗药物之一。虽然非常有效，但铂类药物的临床应用受到其毒性特征以及次优药代动力学特性的限制。因此，开发新型铂类类似物药物并设计新的铂类药物制剂以进一步提高治疗率是肿瘤学的重点研究领域之一。这些努力导致了铂类似物的开发，包括奈达铂、庚铂和洛铂。此外，使用脂质体重新配制铂类药物已导致 L-NDPP (Aroplatin™)、SPI-77、Lipoplatin™、Lipoxal™ 和 LiPlaCis® 的开发。脂质体具有多种有吸引力的生物活性，包括生物相容性、高载药量和改善的药代动力学，非常适合铂类药物输送。在这篇综述中，我们讨论了各种铂类药物及其使用基于脂质体的药物递送载体的递送。我们比较和对比不同的脂质体平台，并推测铂类药物输送研究的未来。
Platinum-based chemotherapy, such as cisplatin, oxaliplatin, and carboplatin, is one of the most widely utilized classes of cancer therapeutics. While highly effective, the clinical applications of platinum-based drugs are limited by their toxicity profiles as well as suboptimal pharmacokinetic properties. Therefore, one of the key research areas in oncology has been to develop novel platinum analog drugs and engineer new platinum drug formulations to improve the therapeutic ratio further. Such efforts have led to the development of platinum analogs including nedaplatin, heptaplatin, and lobaplatin. Moreover, reformulating platinum drugs using liposomes has resulted in the development of L-NDPP (Aroplatin™), SPI-77, Lipoplatin™, Lipoxal™, and LiPlaCis®. Liposomes possess several attractive biological activities, including biocompatibility, high drug loading, and improved pharmacokinetics, that are well suited for platinum drug delivery. In this review, we discuss the various platinum drugs and their delivery using liposome-based drug delivery vehicles. We compare and contrast the different liposome platforms as well as speculate on the future of platinum drug delivery research.